NCT00497497已完成1 期
A Phase Ib, Dose-Escalation Study of the Safety and Pharmacokinetics of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 主要终点
- Incidence and nature of dose-limiting toxicities
研究概览
简要总结
This is a Phase Ib, open-label, multicenter, dose-escalation study designed to assess if PRO95780 in combination with two different irinotecan-containing regimens is safe and tolerable in patients with metastatic colorectal cancer (mCRC) who have progressed following, or cannot tolerate, first-line therapy with 5-fluorouracil-, oxaliplatin-, and bevacizumab-containing regimens. This study will also make a preliminary assessment of the anti-tumor activity of PRO95780 in combination with irinotecan and cetuximab or the FOLFIRI regimen plus bevacizumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Age ≥ 18 years
- •Histologically confirmed CRC with evidence of metastases and measurable tumor lesions
- •Documented disease progression following, or intolerance to, treatment with 5-fluorouracil, oxaliplatin, and bevacizumab-based therapy
- •Life expectancy > 3 months
- •For patients of reproductive potential (males and females), use of reliable means for contraception (e.g., contraceptive pill, intrauterine device [IUD], physical barrier) throughout the trial and for 6 months following their final exposure to study treatment
- •Willingness and capability to be accessible for study follow-up
排除标准
- •Patients who have a Kras mutation will be excluded from receiving cetuximab-containing regimens
- •Prior radiotherapy to a measurable metastatic lesion(s) to be used for response assessment, unless the lesion has progressed subsequent to the radiotherapy
- •Recent radiotherapy to a peripheral lesion, thoracic, abdominal, or pelvic field
- •Recent chemotherapy, hormonal therapy, or immunotherapy
- •Evidence of clinically detectable ascites
- •Other invasive malignancies within 5 years
- •History or evidence of active central nervous system (CNS) disease
- •Current or recent participation in another experimental drug study
- •Clinically significant cardiovascular disease
- •Active infection requiring parenteral antibiotics
- •Recent major surgical procedure, open biopsy, significant traumatic injury, fine needle aspirations, or anticipation of need for major surgical procedure during the course of the study
- •Known or suspected to be positive for the human immunodeficiency virus (HIV)
- •Known to be positive for hepatitis C or hepatitis B surface antigen
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or specified study treatment
- •Pregnancy (positive pregnancy test) or breast feeding
- •Serious, non-healing wound, ulcer, or bone fracture
- •Known sensitivity to any of the products administered during the study
- •Any disorder that compromises the ability of the patient to provide written informed consent and/or comply with study procedures
研究组 & 干预措施
1
Experimental
干预措施: cetuximab (Drug)
1
Experimental
干预措施: irinotecan (Drug)
1
Experimental
干预措施: PRO95780 (Drug)
2
Experimental
干预措施: bevacizumab (Drug)
2
Experimental
干预措施: FOLFIRI regimen (Drug)
2
Experimental
干预措施: PRO95780 (Drug)
结局指标
主要结局
Incidence and nature of dose-limiting toxicities
时间窗: Through study completion or early study discontinuation
次要结局
- Incidence, nature, and severity of adverse events(Through study completion or early study discontinuation)
- Incidence and severity of infusion reactions(Through study completion or early study discontinuation)
- Change in vital signs(Through study completion or early study discontinuation)
研究者
相似试验
已完成
1 期
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid TumorsSolid CancersNCT01332604Genentech, Inc.41
Unknown
1 期
A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT02453464Jiangsu Simcere Pharmaceutical Co., Ltd.36
Unknown
1 期
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.Ovarian CancerNCT03763123Jiangsu Simcere Pharmaceutical Co., Ltd.48
已完成
1 期
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid TumorsNeoplasmsNCT01362374Genentech, Inc.122
终止
1 期
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid TumorsSolid TumorsNCT00996892Genentech, Inc.178